While our findings expose challenges associated with achieving the specific delivery of folate–miR-34a to PCa, we provide evidence that folate–miR-34a may be a therapeutic agent for FOLR1-expressing cancers including ovarian and cervical cancers. The gene discussed is FOLR1; the disease is cervical cancer.